Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2

Current Oncology Reports

Volumn 13, Issue 2, 2011, Pages 97-102

  Spratlin, Jennifer ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angiogenesis; IMC 1121B; Monoclonal antibody; Ramucirumab; Targeted therapy; Vascular endothelial growth factor receptor

Indexed keywords

AFLIBERCEPT; ALACIZUMAB PEGOL; BEVACIZUMAB; BRIVANIB; CARBOPLATIN; CEDIRANIB; DACARBAZINE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ARTHRALGIA; ASTHENIA; BACKACHE; BRAIN HEMORRHAGE; BREAST CANCER; CANCER SURVIVAL; CANCER THERAPY; CHEMOTHERAPY INDUCED EMESIS; COLON CANCER; COLORECTAL CANCER; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DYSPNEA; EPISTAXIS; EXTRACELLULAR MATRIX; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HAND FOOT SYNDROME; HEADACHE; HEART INFARCTION; HOARSENESS; HUMAN; HYPERTENSION; HYPOTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; NAUSEA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PERIPHERAL EDEMA; POLYNEUROPATHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; PROTEINURIA; RASH; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMACH CANCER; SYNCOPE; THROMBOSIS; THYMOMA; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TUMOR BLEEDING; UPPER RESPIRATORY TRACT INFECTION; UTERUS MYOMA; UTERUS SARCOMA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79955798791     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0149-5     Document Type: Review

References (40)

1. Hyder, S.M. and G.M. Stancel, Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Mol Endocrinol, 1999. 13(6): p. 806-11.
2. Folkman, J., Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1995. 1(1): p. 27-31.
3. Carmeliet, P. and R.K. Jain, Angiogenesis in cancer and other diseases. Nature, 2000. 407(6801): p. 249-57.
4. Neufeld, G., T. Cohen, S. Gengrinovitch, et al., Vascular endothelial growth factor (VEGF) and its receptors. Faseb J, 1999. 13(1): p. 9-22.
5. Veikkola, T. and K. Alitalo, VEGFs, receptors and angiogenesis. Semin Cancer Biol, 1999. 9(3): p. 211-20.
6. Li, B., G. Fuh, G. Meng, et al., Receptor-selective variants of human vascular endothelial growth factor. Generation and characterization. J Biol Chem, 2000. 275(38): p. 29823-8.
7. Gille, H., J. Kowalski, B. Li, et al., Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem, 2001. 276(5): p. 3222-30.
8. Leung, D.W., G. Cachianes, W.J. Kuang, et al., Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 1989. 246(4935): p. 1306-9.
9. Lee, J.C., N.H. Chow, S.T. Wang, et al., Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer, 2000. 36(6): p. 748-53.
10. Kaya,A., A. Ciledag, B.E. Gulbay, et al., The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med, 2004. 98(7): p. 632-6.
11. Lecourtois, M., C. Alexandre, L. Dubois, et al., Wingless capture by Frizzled and Frizzled2 in Drosophila embryos. Dev Biol, 2001. 235(2): p. 467-75.
12. Plate, K.H., G. Breier, H.A. Weich, et al., Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer, 1994. 59(4): p. 520-9.
13. Witte, L., D.J. Hicklin, Z. Zhu, et al., Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev, 1998. 17(2): p. 155- 61.
14. Zhu, Z. and L. Witte, Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs, 1999. 17(3): p. 195-212.
15. Zhu, Z., P. Bohlen, and L. Witte, Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr Cancer Drug Targets, 2002. 2(2): p. 135-56.
16. Gordon, M.S., K. Margolin, M. Talpaz, et al., Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol, 2001. 19(3): p. 843-50. This is a phase 1 study of bevacizumab.
17. Holash, J., S. Davis, N. Papadopoulos, et al., VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A, 2002. 99(17): p. 11393-8.
18. Byrne, A.T., L. Ross, J. Holash, et al., Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res, 2003. 9(15): p. 5721-8.
19. Huang, J., J.S. Frischer, A. Serur, et al., Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A, 2003. 100(13): p. 7785-90.
20. Fukasawa, M. and M. Korc, Vascular endothelial growth factortrap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res, 2004. 10(10): p. 3327-32.
21. Tew, W.P., M. Gordon, J. Murren, et al., Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res, 2010. 16(1): p. 358-66.
22. Lockhart, A.C., M.L. Rothenberg, J. Dupont, et al., Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol. 28(2): p. 207-14.
23. Chu, Q.S., Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther, 2009. 9(2): p. 263-71.
24. Awada, A., A. Hendlisz, T. Gil, et al., Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/ 7 days off in patients with advanced, refractory solid tumours. Br J Cancer, 2005. 92(10): p. 1855-61. This is a phase 1 study of sorafenib.
25. Faivre, S., C. Delbaldo, K. Vera, et al., Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol, 2006. 24(1): p. 25-35. This is a phase 1 study of sunitinib.
26. Britten, C.D., F. Kabbinavar, J.R. Hecht, et al., A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol, 2008. 61(3): p. 515-24. This is a phase 1 study of sunitinib.
27. Strumberg, D., H. Richly, R.A. Hilger, et al., Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol, 2005. 23(5): p. 965-72. This is a phase 1 study of sorafenib.
28. Moore, M., H.W. Hirte, L. Siu, et al., Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol, 2005. 16 (10): p. 1688-94. This is a phase 1 study of sorafenib.
29. Ton, N.C., G.J. Parker, A. Jackson, et al., Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res, 2007. 13 (23): p. 7113-8.
30. Posey, J.A., T.C. Ng, B. Yang, et al., A phase I study of antikinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res, 2003. 9(4): p. 1323-32.
31. Lu, D., X. Jimenez, H. Zhang, et al., Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer, 2002. 97(3): p. 393-9.
32. Imclone Systems Incorporated, Investigator's Brochure. 2010.
33. Lu, D., J. Shen, M.D. Vil, et al., Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem, 2003. 278(44): p. 43496-507.
34. Zhu, Z., K. Hattori, H. Zhang, et al., Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia, 2003. 17(3): p. 604-11.
35. Spratlin, J.L., R.B. Cohen, M. Eadens, et al., Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 28(5): p. 780-7. This is a phase 1 study of ramucirumab administered weekly.
36. Chiorean, E., C. Sweeney, H. Hurwitz, et al., Phase I dose-escalation study of the anti-VEGFR-1 recombinant human IgG1 MAb IMC-1121B administered every other weeks (q2W) or every 3 (q3w) in patients (pts) with advanced cancers. Molecular Targets and Cancer Therapeutics, 2007. Conference Proceedings Abstract B15. This is a phase 1 study of ramucirumab administered every 2 or 3 weeks.
37. Garcia, J.A., G.R. Hudes, T.K. Choueiri, et al. Phase II study of IMC-1121B in patients with metastatic renal cancer (mRCC) following VEGFR-2 tyrosine kinase inhibitor (TKI) therapy (IMCL CP12-0605/NCT00515697). in 2010 Genitourinary Cancers Symposium 2010. This is a phase 2 study of ramucirumab in RCC.
38. Camidge, D.R., M.S. Ballas, S. Dubey, et al., A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2010. 28:15s, 2010 (suppl; abstr 7588). This is a phase 2 study of ramucirumab in lung cancer.
39. Carvajal, R.D., M.K. Wong, J.A. Thompson, et al., A phase II randomized study of ramucirumab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM). J Clin Oncol 2010. 28:15s, 2010 (suppl; abstr 8519∧) This is a phase 2 study of ramucirumab in malignant melanoma.
40. Zhu, A.X., R.S. Finn, M. Mulcahy, et al. A phase 2 study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC): Updated results (CP12-0710/NCT00627042). in International Liver Cancer Association Fourth Annual Conference 2010. Montreal, Quebec, Canada. This is a phase 2 study of ramucirumab in HCC.